Evidence map›Paper›PMID 42465462›Full record

ArticlebioRxiv : the preprint server for biology2026

Ebola virus exploits host lncRNA

Olena Shtanko, Tanuj Gunturu, Anu Gopal, Marija Djurkovic-Lopez, Hoang Nguyen, Sahana Jayakumar, Ajai Lawrence D'Silva, Asha Thomas, Smita Kulkarni

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Olena ShtankoTexas Biomedical Research Institute, San Antonio, Texas 78227, USA.
Tanuj GunturuTexas Biomedical Research Institute, San Antonio, Texas 78227, USA.
Anu GopalTexas Biomedical Research Institute, San Antonio, Texas 78227, USA.
Marija Djurkovic-LopezTexas Biomedical Research Institute, San Antonio, Texas 78227, USA.
Hoang NguyenTexas Biomedical Research Institute, San Antonio, Texas 78227, USA.
Sahana JayakumarTexas Biomedical Research Institute, San Antonio, Texas 78227, USA.
Ajai Lawrence D'SilvaTexas Biomedical Research Institute, San Antonio, Texas 78227, USA.
Asha ThomasTexas Biomedical Research Institute, San Antonio, Texas 78227, USA.
Smita KulkarniTexas Biomedical Research Institute, San Antonio, Texas 78227, USA.

Funding

Role of cellular long non-coding RNAs in HIV replication and disease outcomeR01AI157850 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI KULKARNI, SMITA · 2022 to 2025
$2.0M
NIAID NIH HHS R01 AI157850
6 · The paper itself

Abstract

Ebola virus (EBOV) infection causes severe hemorrhagic fever marked by dysregulated cytokine production, impaired antiviral defenses, and multi-organ failure. Macrophages are primary targets of EBOV, and viral replication profoundly alters macrophage transcriptional programs, driving hyperinflammation. Although long non-coding RNAs (lncRNAs) are increasingly recognized as regulators of immunity and viral pathogenesis, their roles in EBOV infection remain poorly understood. We performed comprehensive transcriptomic profiling of primary human monocyte-derived macrophages infected with the highly pathogenic EBOV Mayinga variant. Infection triggered extensive remodeling of both coding and non-coding transcriptomes, including hundreds of differentially expressed lncRNAs. Functional analysis of neighboring protein-coding genes of EBOV-induced lncRNAs (EVILs) revealed enrichment of pathways linked to cytokine signaling, transcriptional regulation, and cell signaling, all of which are central to Ebola virus disease (EVD) pathogenesis. Among the most strongly induced EVILs, LINC01740 and its neighboring protein-coding gene, Activating Transcription Factor 3 (ATF3), were significantly upregulated. Antisense oligonucleotide-mediated inhibition of LINC01740 reduced ATF3 mRNA and protein levels. CRISPR/Cas13d-mediated knockdown of ATF3 restored type I interferon (IFN-I) signaling and antiviral gene expression in EBOV-infected macrophages. Mechanistically, ATF3 functions as a negative regulator of IFN-I and type I interferon-stimulated gene expression, thereby suppressing antiviral immune responses in EBOV-infected macrophages. Together, these findings identify a previously unrecognized LINC01740-ATF3-IFN-I regulatory axis that EBOV exploits to promote immune suppression and viral replication.

Identifiers

PMID42465462
PMCPMC13370357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.